4D Molecular Therapeutics Q2 FY26 net loss widens to $72.94 million; revenue rises to $3.78 million

Reuters2026/08/13 20:12

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

4D Molecular Therapeutics posted a Q2 2026 net loss of USD 72.94 million, widening from USD 54.66 million a year earlier.
Revenue rose to USD 3.78 million from USD 15,000, driven by Otsuka clinical-trial cost sharing and reimbursements.
RD expense climbed to USD 68.28 million from USD 47.95 million, reflecting execution of 4D-150 Phase 3 trials in wet AMD.
Cash, cash equivalents, marketable securities totaled USD 430.63 million at June 30, down from USD 514.03 million at year-end 2025; runway seen into H2 2028.
4D-150 4FRONT-1 topline data expected in Q2 2027; 4FRONT-2 topline data expected in H2 2027, with a DME Phase 3 start targeted for Q3 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4D Molecular Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608131605PRIMZONEFULLFEED9809218) on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

4D Molecular Therapeutics Q2 FY26 net loss widens to $72.94 million; revenue rises to $3.78 million

You may also like

Crypto prices